首頁 > 市場調查報告書 > 製藥

癌症分子標靶治療學

市場調查報告書

商品編碼

1473015

PIM 激酶標靶治療的全球市場：市場機會與臨床試驗的見解 (2024)

Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024

出版日期: 2024年05月01日 | 出版商:

KuicK Research | 英文 93 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

PIM 激酶由三種絲氨酸/蘇氨酸蛋白激酶組成，由於其在癌症和其他疾病中的關鍵作用而引起了臨床和商業的廣泛關注。PIM 激酶作為一個有前景的治療標靶，為開發旨在解決各種疾病領域未滿足的醫療需求的標靶療法提供了令人興奮的前景。儘管 PIM 激酶標靶治療市場仍處於起步階段，但正在進行的研究工作表明這一新藥物類別的治療前景。

PIM 激酶是莫洛尼鼠白血病病毒原病毒插入位點激酶的縮寫，在調節細胞存活、增殖和分化中發揮關鍵作用，使其成為治療幹預的有吸引力的靶點。PIM 激酶訊號傳導異常與癌症、自體免疫疾病、發炎性疾病、心血管疾病和病毒性疾病有關，凸顯了其廣泛的治療潛力。因此，靶向PIM激酶有望促使可應用於多種適應症的新治療方法的開發。

PIM激酶抑制劑的開發代表了標靶治療領域的一個重要里程碑。多年來，已經開發了多種針對 PIM 激酶的小分子抑制劑，包括 SGI-1776、MEN1703、SGI-1776、ETH-155008 和 JP11646。這些候選藥物主要選擇性地針對 PIM 激酶的 ATP 結合袋，抑制其催化活性並抑制參與疾病進展的下游訊號路徑。SGI-1776、ETH-155008等多種藥物進入臨床試驗凸顯了人們對利用PIM激酶作為治療標靶日益增長的興趣，而PIM激酶抑制則是該藥物走向商業化的一個重要里程碑。

儘管數量有限的 PIM 激酶抑制劑已進入臨床試驗，但 PIM 激酶標靶治療領域的特點是擁有大量處於臨床前開發的候選化合物。許多公司和學術機構正在積極從事研究和開發，旨在尋找具有更高功效和安全性的新型抑制劑。正在進行的臨床試驗正在研究PIM激酶抑制劑在多種癌症適應症（如白血病、多發性骨髓瘤和前列腺癌）以及發炎性疾病（如係統性紅斑狼瘡）的安全性和耐受性。

該報告調查了全球 PIM 激酶靶向治療市場，並提供了市場概述，以及依適應症、公司、國家、細分市場、臨床試驗趨勢以及進入市場的公司的競爭趨勢進行的趨勢。

PIM Kinase Targeted Therapies In Clinical Trials: > 10 Therapies
PIM Kinase Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
USA Dominating PIM Kinase Targeted Therapies Clinical Trials Landscape: > 5 Therapies
Role Of PIM Kinases as Diagnostic & Prognostic Markers
FDA Orphan Designation To PIM Kinase Therapies By indication
Proprietary Development Technologies By Companies

PIM kinases, comprising three serine/threonine protein kinases, have garnered significant attention in both clinical and commercial spheres due to their pivotal roles in cancer and other disease indications. As promising therapeutic targets, PIM kinases offer exciting prospects for the development of targeted therapies aimed at addressing unmet medical needs across various diseases area. Though the market of PIM kinase targeted therapies is still in a budding phase, ongoing research efforts point towards a fruitful future for this emerging drug class.

PIM kinases, standing for Proviral Insertion Site in Moloney Murine Leukemia Virus kinases, play crucial roles in regulating cell survival, proliferation and differentiation, making them attractive targets for therapeutic intervention. Dysregulated PIM kinase signaling has been implicated in cancer, autoimmune disorders, inflammatory conditions, cardiovascular diseases and viral diseases, highlighting their broad therapeutic potential. As such, targeting PIM kinases holds promise for development of novel treatments with potential applications across a diverse range of indications.

The development of PIM kinases inhibitors represents a significant milestone in the field of targeted therapy. Over the years, several small molecule inhibitors targeting PIM kinases have been developed, with notable examples including SGI-1776, MEN1703, SGI-1776, ETH-155008, JP11646. These candidates majorly target the ATP-binding pocket of PIM kinases selectively, inhibiting their catalytic activity and disrupting downstream signaling pathways implicated in disease progression. The advancement of some of these such as SGI-1776, ETH-155008 into clinical trials underscores the growing interest in exploiting PIM kinases as therapeutic targets and represents a key milestone in moving PIM kinase inhibitors towards commercialization.

While only a limited number of PIM kinase inhibitors have progressed to clinical trials, the landscape of PIM kinase targeted therapies is characterized by a robust pipeline of candidates in preclinical development. Numerous companies and academic institutions are actively engaged in research and development efforts aimed at identifying novel inhibitors with improved efficacy and safety profiles. Ongoing clinical trials are evaluating the safety, tolerability and efficacy of PIM kinase inhibitors in various cancer indications, including leukemia, multiple myeloma and prostate cancer, as well as inflammatory conditions like systemic lupus erythematosus.

Collaborations between pharmaceutical companies, academic institutions and research hospitals have been instrumental in driving progress in the development of PIM kinase targeted therapies. Academic institutions like University of Arizona, University of Leipzig, Ludwig Maximilians University Munich, University of Alabama, Ohio State University, Medical University of South Carolina and Pusan National University have over the years contributed valuable insights into the underlying biology of PIM kinases and their role in disease pathogenesis. Companies on the other hand bring expertise in drug discovery and development while hospitals serve as places to conduct clinical trials and additional research.

The development of RF-1302, a novel dual inhibitor of PIM-1 and FLT3 kinases, by the Chinese Academy of Medical Science and Tianjin Medical University General Hospital in partnership with Ruifu Therapeutics, serves as an example of this. The candidate is presently undergoing preclinical studies to treat acute myeloid leukemia. This kind of collaborative spirit encourages innovation and speeds up the translation of fundamental research discoveries into treatment interventions that have practical application. Companies and academic institutions can accelerate the commercialization of PIM kinase targeted therapies and optimize their potential by utilizing complementary capabilities and resources.

The market for PIM kinase targeted therapies looks to have a promising future with lots of scope to grow. Structure-based drug design and high-throughput screening are two examples of how drug discovery technologies are progressing and could lead to the development of new PIM kinase inhibitors with better potency and selectivity. Furthermore, the development of precision medicine strategies and biomarker-driven methodologies may make it possible to implement more individualized and focused treatment plans, improving the therapeutic utility of PIM kinase targeted therapies.

Additionally, novel treatment approaches may be discovered as a result of our growing understanding of PIM kinase biology and its significance in the pathophysiology of disease. PIM kinase targeted therapy development will be accelerated by industry-academia collaborations, which will ultimately benefit patients by offering more individualized and effective treatment alternatives. Because of this, the market for PIM kinase targeted therapies is anticipated to experience rapid expansion and innovation in the years to come, presenting intriguing prospects for players in the pharmaceutical sector.

1. Introduction to PIM Kinase Targeted Therapy

1.1 Overview
1.2 History, Development & Evolution

2. PIM Kinase Targeted Therapy Approaches

2.1 Small Molecule Inhibitors
2.2 PROTAC Degraders
2.3 RNA Interference
2.4 CRISPR/Cas9

3. PIM Kinase Targeted Therapy Combinations for Cancer Treatment

3.1 Chemotherapy
3.2 Targeted Therapies
3.3 Radiotherapy
3.4 Immunotherapy

4. PIM Kinases as Diagnostic & Prognostic Markers

5. Global PIM Kinase Targeted Therapies Research & Market Trends by Indication

5.1 Cancer
5.2 Autoimmune & Inflammatory Disorders
5.3 Cardiovascular Diseases
5.4 Viral Diseases
5.5 Neurodegenerative Diseases

6. PIM Kinase Therapies - Proprietary Development Technologies By Companies

7. Global PIM Kinase Targeted Therapies Market Overview

7.1 Current Market Scenario
7.2 Future Commercialization Outlook
7.3 Favorable Developmental Parameters
7.4 Key Challenges & Restraints

8. PIM Kinase Targeted Therapies Research & Development Trends By Region

8.1 US
8.2 Europe
8.3 Japan
8.4 China

9. PIM Kinase Therapies - FDA Orphan Designation By Indication

10. Global PIM Kinase Inhibitor Clinical Trials Overview

10.1 By Phase
10.2 By Country
10.3 By Company
10.4 By Indication
10.5 Patient Segment

11. Global PIM Kinase Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

11.1 Preclinical
11.2 Phase I
11.3 Phase I/II
11.4 Phase II

12. Competitive Landscape

12.1 Akros Pharma
12.2 Biolexis Therapeutics
12.3 Inflection Biosciences
12.4 Menarini group
12.5 Mysthera Therapeutics
12.6 Novartis
12.7 Shengke Pharmaceutics
12.8 Sumitomo Pharma America

簡介目錄圖表

List of Figures

Figure 1-1: PIM Kinase Targeted Therapies - Developmental Milestones
Figure 2-1: PIM Kinase Targeted Therapy - Current Approaches
Figure 2-2: PIM Kinase Small Molecule Inhibition - Future Opportunities
Figure 2-3: PROTACs - Advantages
Figure 2-4: PROTACs - Future Opportunities
Figure 2-5: CRISPR/Cas9 - Benefits as a Therapeutic Modality
Figure 2-6: Effects of CRISPR/Cas9-mediated DSB repair mechanism on PIM Kinase activity
Figure 3-1: Combination of PIM Targeted Therapies & Chemotherapy - Benefits
Figure 3-2: Combination of PIM Targeted therapies & Immunotherapy - Benefits
Figure 5-1: PIM Kinases - Functions in Viral Infections
Figure 6-1: Biolexis Therapeutics - MolecuLern Process
Figure 7-1: PIM Kinase Targeted Therapies - Future Opportunities
Figure 7-2: Global PIM Kinase Targeted Therapies Market - Drivers & Opportunities
Figure 7-3: Global PIM Kinase Targeted Therapies Market - Challenges & Restraints
Figure 9-1: Regulatory Designations - Benefits
Figure 10-1: Global - PIM Kinase Targeted Therapies Clinical Trials By Phase (Numbers), 2024
Figure 10-2: Global - PIM Kinase Targeted Therapies Clinical Trials By Country (Numbers), 2024
Figure 10-3: Global - PIM Kinase Targeted Therapies Clinical Trials By Company (Numbers), 2024
Figure 10-4: Global - PIM Kinase Targeted Therapies Clinical Trials By Indication (Numbers), 2024
Figure 10-5: Global - PIM Kinase Targeted Therapies Clinical Trials By Patient Segment (Numbers), 2024

List of Tables

Table 5-1: Cancer - PIM inhibitors in Clinical Development
Table 5-2: Autoimmune & Inflammatory Disorders - PIM inhibitors in Clinical Development
Table 5-3: Cardiovascular Diseases - PIM inhibitors in Clinical Development
Table 9-1: PIM Kinase Therapies - FDA Orphan Designation By Indication

02-2729-4219

+886-2-2729-4219